KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Total Debt (2016 - 2025)

Biogen has reported Total Debt over the past 16 years, most recently at $6.3 billion for Q4 2025.

  • For Q4 2025, Total Debt changed 0.14% year-over-year to $6.3 billion; the TTM value through Dec 2025 reached $6.3 billion, changed 0.14%, while the annual FY2025 figure was $6.3 billion, 0.14% changed from the prior year.
  • Total Debt for Q4 2025 was $6.3 billion at Biogen, up from $150.0 million in the prior quarter.
  • Over five years, Total Debt peaked at $6.9 billion in Q4 2023 and troughed at $150.0 million in Q2 2025.
  • A 5-year average of $4.5 billion and a median of $6.3 billion in 2022 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: skyrocketed 528.67% in 2022 and later decreased 9.26% in 2024.
  • Year by year, Total Debt stood at $999.1 million in 2021, then skyrocketed by 528.67% to $6.3 billion in 2022, then increased by 10.46% to $6.9 billion in 2023, then decreased by 9.26% to $6.3 billion in 2024, then decreased by 0.14% to $6.3 billion in 2025.
  • Business Quant data shows Total Debt for BIIB at $6.3 billion in Q4 2025, $150.0 million in Q2 2025, and $6.3 billion in Q4 2024.